Market Overview - On September 1, the A-share market experienced fluctuations, with the Shanghai Composite Index rising by 0.12%, the Shenzhen Component Index by 0.11%, and the ChiNext Index by 0.55% [1] - The total trading volume for the market reached 1.85 trillion yuan, slightly lower than the previous day, with over 3,100 stocks rising [1] Key Stocks and Sectors - The top trading stock was Cambrian (688256) with a trading volume of 18.6 billion yuan, followed by Xinyi (300502), Zhongji (300308), and Dongfang Caifu (300059), each exceeding 10 billion yuan in trading volume [1][2] - The precious metals, innovative pharmaceuticals, film and television, tourism, and storage chip sectors saw significant gains, while insurance, military equipment, securities, and airport shipping sectors experienced pullbacks [2] Precious Metals Sector - The precious metals sector surged, with stocks like Haixing (603115), Jintong (601958), and Shengda Resources (000603) hitting the daily limit, while Hunan Gold (002155) and Luoyang Molybdenum (603993) also saw gains [4] - The rise in precious metals is attributed to the recent increase in the U.S. core PCE index, which aligns with expectations for a Federal Reserve rate cut, enhancing the appeal of precious metals as safe-haven assets amid geopolitical risks and trade tensions [4][6] Innovative Pharmaceuticals Sector - The innovative pharmaceutical sector showed strong performance, with Maiwei Bio (688062) hitting the daily limit and other stocks like Baihua Pharmaceutical (600721) and First Pharmaceutical (600833) also experiencing significant gains [7][8] - Maiwei Bio announced the approval of its two biosimilar products in Pakistan, marking a significant milestone as the first biosimilar approved in the country, and has also entered a licensing agreement with Calico Life Sciences for global rights outside Greater China [9] - The recent adjustments in the national medical insurance catalog are expected to increase the attractiveness of innovative drugs, with a focus on new drugs and unique products [9]

Core Viewpoint - Maiwei Biotech has received registration approval for two biosimilar drugs, 9MW0311 and 9MW0321, from the Drug Regulatory Authority of Pakistan, marking a significant milestone in the company's global commercialization strategy [1][4]. Drug Information - 9MW0311 (Rexeva) is approved for osteoporosis treatment in postmenopausal women at high risk of fractures, with a specification of 60mg and registration number 127267 [1]. - 9MW0321 (Denosu) is approved for treating giant cell tumor of bone (GCTB) in adults and adolescents, with a specification of 120mg and registration number 127268 [2]. Market Potential - Pakistan, with a population of 240 million, represents a significant emerging market for pharmaceuticals, driven by increasing medical demand [1]. - The global market for denosumab drugs for osteoporosis treatment is projected to reach $1.317 billion in 2024 [2]. International Expansion - The company has signed formal cooperation agreements with 30 countries, including Brazil, Colombia, and Indonesia, to expand the market for 9MW0311 and 9MW0321 [3]. - Registration applications for these drugs have been submitted to five additional countries, including Jordan and Egypt, with more applications in preparation [3]. Competitive Advantage - The approval of these biosimilars enhances the company's core competitiveness and supports its ongoing efforts to penetrate emerging markets [4].